GE Healthcare is partnering with artificial intelligence (AI) developer MedyMatch Technology on its AI-based clinical decision-support software. MedyMatch will integrate its intracranial hemorrhage detection software into GE's CT systems to aid in the assessment of patients suspected of having acute head trauma or stroke, when intracranial hemorrhage is suspected. Upon regulatory clearance, the software will be implemented as an image-based decision-support tool supporting a second-read capability for physicians, identifying suspected intracranial hemorrhage in stroke and head trauma patients. Separately, MedyMatch's technology will also be deployed to aid in patient case prioritization, the firms said.

Artificial intelligence (AI) gives machines the ability to "think" and accomplish tasks. AI already is a big part of our lives in areas such as banking, shopping, security and healthcare. Soon it will help us get around in automated vehicles. By 2025, the global enterprise AI market is predicted to be worth more than $30 billion. Israeli industry can expect a nice piece of that pie due to its world-class capabilities in AI and its subsets: big-data analysis, natural-language processing, computer vision, machine learning and deep learning.

Artificial intelligence (AI) gives machines the ability to "think" and accomplish tasks. AI already is a big part of our lives in areas such as banking, shopping, security and healthcare. Soon it will help us get around in automated vehicles. By 2025, the global enterprise AI market is predicted to be worth more than $30 billion. Israeli industry can expect a nice piece of that pie due to its world-class capabilities in AI and its subsets: big-data analysis, natural-language processing, computer vision, machine learning and deep learning.

"We are on the threshold of the next evolutionary step in Imaging," Gene Saragnese, chairman and CEO of Israel-based MedyMatch, said in the release. "Imaging technological development has been historically focused on providing clinicians [with] the best possible image, optimizing spatial and temporal resolution, coverage and dose.

Above the Trend Line: machine learning industry rumor central, is a recurring feature of insideBIGDATA. In this column, we present a variety of short time-critical news items such as people movements, funding news, financial results, industry alignments, rumors and general scuttlebutt floating around the big data, data science and machine learning industries including behind-the-scenes anecdotes and curious buzz. Our intent is to provide our readers a one-stop source of late-breaking news to help keep you abreast of this fast-paced ecosystem. We're working hard on your behalf with our extensive vendor network to give you all the latest happenings. Be sure to Tweet Above the Trend Line articles using the hashtag: #abovethetrendline.

MedyMatch Technology Ltd., ("MedyMatch") the deep learning and artificial intelligence company, announced that after several years of extensive research and development, it has achieved a major milestone in the availability, for research, of an artificial intelligence based technology that can help detect the presence of intracranial hemorrhage or brain bleed which can occur in cases of brain trauma and stroke. Subtle bleeds are difficult to detect and if misinterpreted or missed by a physician can lead to serious patient injury and even death. Per the American Heart Association and American Stroke Association (AHA/ASA), stroke is the fourth leading cause of death and one of the top causes of preventable disability in the United States. Affecting 4% of U.S. adults, it is forecasted that by 2030 there will be approximately 3.4 million stroke victims annually in the U.S., costing the healthcare system $240 Billion on an annual basis. It is anticipated that this new technology will come to the marketplace in several forms: a patient specific computer assisted detection ("CAD") tool used by physicians in the emergency room to assist in the detection of intracranial bleeds; a prioritization algorithm operating within a PACS or on a CT to help prioritize cases based on the potential presence of a bleed; and as a tool to provide insights into populations to proactively identify bleed cases. Deployment will be customer driven as either a cloud or on-premises based solution, with near zero foot-print and seamless integration into a hospital enterprise, integrating smoothly into clinical workflow.

MedyMatch Technology, a company based in Tel Aviv, Israel, leverages artificial intelligence, deep learning, and computer vision technologies to offer patient-specific clinical decision support. Their application helps radiologists and emergency room physicians to detect signs of intracranial hemorrhages, which are difficult to diagnose by standard analysis of imaging data alone. The Medgadget team recently had an opportunity to speak with Gene Saragnese, Chairman and Chief Executive Officer of MedyMatch, to discuss their technology and its significance in depth. Prior to joining MedyMatch in January of 2016, Gene was the Chief Executive Officer of Philips Imaging and a member of Philips Healthcare's Executive Team. A graduate of Rutgers College of Engineering in New Jersey, he has also previously served as GE Healthcare's Chief Technology Officer and has held management roles with GE, RCA, Martin Marietta, and Lockheed Martin.

Stealthy MedyMatch emerged in February with plans to improve emergency room care using cognitive analysis and artificial intelligence. Now, in its first collaboration with a U.S. hospital, the company is developing its first real-time decision-support tool using data from New Jersey-based Capital Health. Under the agreement, Capital Health will supply Israel-based MedyMatch with anonymized data to help it develop the tool, which will target stroke patients. It will analyze medical images and provide the ER radiologist with information to help him or her determine the course of treatment. It combines "deep vision, advanced cognitive analytics and artificial intelligence" to analyze images and identify anomalies that may be invisible to the human eye.

MedyMatch Technology, a startup from Israel that specializes in medical imaging analysis for emergency medicine, has its first U.S. hospital partner. Capital Health, a two-hospital system in New Jersey, will deploy MedyMatch's artificial intelligence-based analytics in the emergency department and help the Tel Aviv-based vendor develop a clinical decision support tool for stroke care. To accomplish the latter, Capital Health, based in Hopewell Township, New Jersey, has agreed to provide MedyMatch with anonymized data from patients, the organizations said Monday. "The data Capital Health will provide will allow us to move closer to providing this decision support tool which can help ensure appropriate diagnosis, critical for treatment," MedyMatch Chairman and CEO Gene Saragnese said in a prepared statement. Saragnese was CEO of Philips Imaging before joining the startup a year ago.

Shepherds – yes, this is a reference to the popular medical drama "Grey's Anatomy" – who work in hospitals around the world may soon get a new assistant. No, not just another intern but an extra pair of virtual eyes to help them better diagnose stroke victims. Tel Aviv-based MedyMatch Technology Ltd., which hopes to have its first commercially available product as soon as the first half of 2017, is developing an artificial intelligence (AI) platform for critical areas of patient care. The platform is meant to help study data more quickly and accurately than the human eye, and help physicians with their clinical decisions in a wide set of healthcare issues. MedyMatch's first area of focus will be for stroke patients.